

# Act Fast: Understanding Flu Prevention and Treatment in At-Risk Populations


Cassandra B. Donnelly, DO Charles P. Vega, MD

### **Learning Objectives**

- After participating in this educational activity, participants should be better able to:
  - Discuss the pathophysiology of influenza A and B viruses
  - Compare antiviral agent indications and selection based on data from completed clinical trials, ongoing studies, and real-world reports
  - Formulate post-exposure prophylaxis strategies based on an antiviral agent's mechanism of action



# Kaplan-Meier Curves of TTIIS in the Modified Intention-to-Treat Population



#### Slide 4

Redraw- prova colors? if possible
Samantha Cojocariu, 6/29/2021

EG5 Done!
Emily Gold, 7/2/2021

SC7 Please make sure All legend colors are consistent.
Samantha Cojocariu, 6/29/2021

EG4 Done!
Emily Gold, 7/2/2021


CD3 x-axis - cap since, start, treatment; y-axis, cap patients, without, improvement
Cindy Davidson, 7/2/2021

### MiniSTONE-2: Time to Alleviation of Influenza Symptoms in Children – Baloxavir vs Oseltamivir

- Phase 3, randomized, controlled trial among healthy children ill <48 hours; aged 1 to 12 years</li>
- Baloxavir single dose: 2 mg/kg if <20 kg, 40 mg if ≥20 kg vs oseltamivir twice daily x 5 days; weight-based dosing
- Randomized 2:1, N = 112/57; 81/54 with confirmed influenza
- Primary endpoint was met: similar safety between baloxavir and oseltamivir

	Baloxavir (hours, 95% CI)	EG3 Oseltamivir (nours, 95% CI)
Time to alleviation of symptoms	138 (117-163)	150 (115-165)
Time to culture negativity	24.2 (23.5-24.6)	75.8 (68.9-97.8)

#### Time to Alleviation of Signs and Symptoms: Similar Between Study Arms





Baker J, et al. *Pediatr Infect Dis J*. 2020;39(8):700-705.

#### Slide 5

Adjust the table to fill some additional space and make bullet points larger Samantha Cojocariu, 6/29/2021

EG3 Done!

Emily Gold, 7/2/2021


SC2 Please change 330 to 336

Samantha Cojocariu, 6/29/2021

EG2 Done

Emily Gold, 7/2/2021

## Change from Baseline in Influenza Infectious Viral Load over Time in the Phase 3 Trial






#### Slide 6

SC3	Redraw- prova colors? if possible Samantha Cojocariu, 6/29/2021
EG1	<b>Done!</b> Emily Gold, 7/1/2021
SC4	barry needs to send legend for *'s Samantha Cojocariu, 6/29/2021
CD5	delete period from vs. Cindy Davidson, 7/2/2021
CD6	change ml to mL Cindy Davidson, 7/2/2021
CD7	tweaked ref Cindy Davidson, 7/2/2021

### BLOCKSTONE: Preventative Treatment with Baloxavir After Exposure to an Infected Household Member – 86% Effective



Baloxavir had a comparable safety profile to placebo (AEs: 22.2% with baloxavir, 20.5% with placebo)



#### SC6 Space between P and <

Samantha Cojocariu, 6/29/2021